Trials / Active Not Recruiting
Active Not RecruitingNCT02393625
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ceritinib (LDK378) | |
| DRUG | Nivolumab |
Timeline
- Start date
- 2015-05-27
- Primary completion
- 2027-04-09
- Completion
- 2027-04-09
- First posted
- 2015-03-19
- Last updated
- 2026-04-02
Locations
12 sites across 8 countries: United States, Australia, Belgium, Canada, Hong Kong, Italy, Singapore, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02393625. Inclusion in this directory is not an endorsement.